Application of linoleic acid coupled prodrug of mycophenolate mofetil in anti-fibrosis or/and anti-tumor drugs
A technology of mycophenolate mofetil and anti-tumor drugs, which is applied in the direction of anti-tumor drugs, drug combinations, medical preparations of non-active ingredients, etc., and can solve the problem of low tumor target lethality, limited therapeutic effect, and short retention time To achieve the effect of prolonging the circulation time in the body, increasing drug accumulation and reducing toxicity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0053] Synthesis of MMF-LA conjugated prodrugs, such as figure 1 shown:
[0054] MMF (65 mg, 0.15 mmol), linoleic acid (42.1 mg, 0.15 mmol) and DMAP (18.3 mg, 0.15 mmol) were sequentially added to a 100 mL round-bottomed flask, dissolved in 4 mL of anhydrous dichloromethane, and then EDC was added dropwise rapidly (23.3 mg, 0.15 mmol). The mixture was stirred at 43°C for 3 hours, and the reaction state was observed by thin layer chromatography. When the reaction was basically completed, the reaction solution was cooled, washed with 0.1M hydrochloric acid solution, saturated sodium bicarbonate, and saturated brine respectively; the organic phase was dried with anhydrous sodium sulfate, filtered, and the filtrate was collected and the solvent was removed under reduced pressure; through column chromatography After chromatographic separation and purification (DCM:MeOH=20:1), the product MMF-LA conjugated prodrug (47 mg, yield 45.1%) was obtained.
[0055] The product MMF-LA con...
Embodiment 2
[0058] (1) Preparation of PEGylated MMF-LA nanoformulations:
[0059] The PEGylated MMF-LA conjugated prodrug prepared in Example 1 was dissolved in DSPE-PEG containing 2k In the dimethyl sulfoxide solvent, a mixed solution was obtained, in which the PEGylated MMF-LA conjugated prodrug and DSPE-PEG 2k The mass ratio of MMF-LA is 10:1; and the mixed solution is injected into the aqueous phase under ultrasonic conditions (the volume ratio of dimethyl sulfoxide and the aqueous phase is 1:9), and the uniformly dispersed PEGylated MMF-LA nanoparticles are obtained by dialysis. formulation, denoted DSPE-PEG 2k Coated MMF-LA nanoformulations.
[0060] as DSPE-PEG 2k The control group coated with MMF-LA nanoformulations, polyacetic acid-polyethylene glycol (PEG 5K -PLA 8K ) in place of the above DSPE-PEG 2k , using the above method to prepare polyacetic acid-PEGylated MMF-LA nano-formulations, denoted as PEG 5K -PLA 8K Coated MMF-LA nanoformulations.
[0061] (2) In vitro kil...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


